The Simultaneous Onset of Pancreatitis and Colitis as Immune-related Adverse Events in a Patient Receiving Nivolumab Treatment for Renal Cell Carcinoma

被引：3

作者：

Yazaki, Tomotaka ^{[1
,2
]}

Moriyama, Ichiro ^{[1
,3
]}

Tobita, Hiroshi ^{[1
,2
]}

Sonoyama, Hiroki ^{[1
]}

Okimoto, Eiko ^{[1
]}

Oka, Akihiko ^{[1
]}

Mishima, Yoshiyuki ^{[1
]}

Oshima, Naoki ^{[1
]}

Shibagaki, Kotaro ^{[1
,4
]}

Kawashima, Kousaku ^{[1
,5
]}

Ishimura, Norihisa ^{[1
]}

Nagami, Taichi ^{[6
]}

Maruyama, Riruke ^{[7
]}

Shiina, Hiroaki ^{[6
]}

Ishihara, Shunji ^{[1
,5
]}

机构：

[1] Shimane Univ, Fac Med, Dept Internal Med 2, Izumo, Shimane, Japan

[2] Shimane Univ Hosp, Div Hepatol, Izumo, Shimane, Japan

[3] Shimane Univ Hosp, Canc Ctr, Izumo, Shimane, Japan

[4] Shimane Univ Hosp, Div Endoscopy, Izumo, Shimane, Japan

[5] Shimane Univ Hosp, Inflammatory Bowel Dis Ctr, Izumo, Shimane, Japan

[6] Shimane Univ, Fac Med, Dept Urol, Izumo, Shimane, Japan

[7] Shimane Univ, Fac Med, Dept Pathol, Organ Pathol Unit, Izumo, Shimane, Japan

来源：

INTERNAL MEDICINE | 2022年 / 61卷 / 10期

关键词：

immune checkpoint inhibitor; immune-related adverse event; pancreatitis; colitis; CHECKPOINT INHIBITOR; ADVANCED MELANOMA; PEMBROLIZUMAB; IPILIMUMAB; SAFETY;

D O I：

10.2169/internalmedicine.7911-21

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Immune checkpoint inhibitors (ICIs), which have anti-tumor effects, are currently approved for treatment of several kinds of advanced malignancies. However, with their increasing use, a variety of immune-related adverse events (irAEs) in administered patients have been reported. We herein report a rare case of the simultaneous onset of acute pancreatitis and colitis as irAEs during nivolumab treatment given to a patient with renal cell carcinoma, who then shown marked improvement with corticosteroid therapy.

引用

页码：1485 / 1490

页数：6

共 23 条

[1] Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer
Antonia, S. J.
Villegas, A.
Daniel, D.
Vicente, D.
Murakami, S.
Hui, R.
Yokoi, T.
Chiappori, A.
Lee, K. H.
de Wit, M.
Cho, B. C.
Bourhaba, M.
Quantin, X.
Tokito, T.
Mekhail, T.
Planchard, D.
Kim, Y. -C.
Karapetis, C. S.
Hiret, S.
Ostoros, G.
Kubota, K.
Gray, J. E.
Paz-Ares, L.
de Castro Carpeno, J.
Wadsworth, C.
Melillo, G.
Jiang, H.
Huang, Y.
Dennis, P. A.
Ozguroglu, M.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (20) : 1919 - 1929
[2] Vedolizumab treatment for immune checkpoint inhibitor-induced enterocolitis
Bergqvist, Viktoria
Hertervig, Erik
Gedeon, Peter
Kopljar, Marija
Griph, Hakan
Kinhult, Sara
Carneiro, Ana
Marsal, Jan
[J]. CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (05) : 581 - 592
[3] Quality of life in patients with advanced renal cell carcinoma given nivolumab versus everolimus in CheckMate 025: a randomised, open-label, phase 3 trial
Cella, David
Gruenwald, Viktor
Nathan, Paul
Doan, Justin
Dastani, Homa
Taylor, Fiona
Bennett, Bryan
DeRosa, Michael
Berry, Scott
Broglio, Kristine
Berghorn, Elmer
Motzer, Robert J.
[J]. LANCET ONCOLOGY, 2016, 17 (07) : 994 - 1003
[4] Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Finn, Richard S.
Qin, Shukui
Ikeda, Masafumi
Galle, Peter R.
Ducreux, Michel
Kim, Tae-You
Kudo, Masatoshi
Breder, Valeriy
Merle, Philippe
Kaseb, Ahmed O.
Li, Daneng
Verret, Wendy
Xu, Derek-Zhen
Hernandez, Sairy
Liu, Juan
Huang, Chen
Mulla, Sohail
Wang, Yulei
Lim, Ho Yeong
Zhu, Andrew X.
Cheng, Ann-Lii
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 382 (20) : 1894 - 1905
[5] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
Gandhi, L.
Rodriguez-Abreu, D.
Gadgeel, S.
Esteban, E.
Felip, E.
De Angelis, F.
Domine, M.
Clingan, P.
Hochmair, M. J.
Powell, S. F.
Cheng, S. Y. -S.
Bischoff, H. G.
Peled, N.
Grossi, F.
Jennens, R. R.
Reck, M.
Hui, R.
Garon, E. B.
Boyer, M.
Rubio-Viqueira, B.
Novello, S.
Kurata, T.
Gray, J. E.
Vida, J.
Wei, Z.
Yang, J.
Raftopoulos, H.
Pietanza, M. C.
Garassino, M. C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
[6] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
Hellmann, M. D.
Paz-Ares, L.
Bernabe Caro, R.
Zurawski, B.
Kim, S. -W.
Carcereny Costa, E.
Park, K.
Alexandru, A.
Lupinacci, L.
de la Mora Jimenez, E.
Sakai, H.
Albert, I.
Vergnenegre, A.
Peters, S.
Syrigos, K.
Barlesi, F.
Reck, M.
Borghaei, H.
Brahmer, J. R.
O'Byrne, K. J.
Geese, W. J.
Bhagavatheeswaran, P.
Rabindran, S. K.
Kasinathan, R. S.
Nathan, F. E.
Ramalingam, S. S.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2020 - 2031
[7] Immune-related Adverse Events Associated with Cancer Immunotherapy: A Review for the Practicing Rheumatologist
Jamal, Shahin
Hudson, Marie
Fifi-Mah, Aurore
Ye, Carrie
[J]. JOURNAL OF RHEUMATOLOGY, 2020, 47 (02) : 166 - 175
[8] Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial
Kang, Yoon-Koo
Boku, Narikazu
Satoh, Taroh
Ryu, Min-Hee
Chao, Yee
Kato, Ken
Chung, Hyun Cheol
Chen, Jen-Shi
Muro, Kei
Kang, Won Ki
Yeh, Kun-Huei
Yoshikawa, Takaki
Oh, Sang Cheul
Bai, Li-Yuan
Tamura, Takao
Lee, Keun-Wook
Hamamoto, Yasuo
Kim, Jong Gwang
Chin, Keisho
Oh, Do-Youn
Minashi, Keiko
Cho, Jae Yong
Tsuda, Masahiro
Chen, Li-Tzong
[J]. LANCET, 2017, 390 (10111) : 2461 - 2471
[9] Immune checkpoint inhibitor-induced gastrointestinal and hepatic injury: pathologists' perspective
Karamchandani, Dipti M.
Chetty, Runjan
[J]. JOURNAL OF CLINICAL PATHOLOGY, 2018, 71 (08) : 665 - 671
[10] First FDA Approval Agnostic of Cancer Site - When a Biomarker Defines the Indication
Lemery, Steven
Keegan, Patricia
Pazdur, Richard
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 377 (15) : 1409 - 1412

← 1 2 3 →